Clearside Biomedical, Inc. announced its exploration of strategic alternatives to advance its suprachoroidal drug delivery platform and maximize stockholder value. The company, which specializes in ...

- Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - The publication, entitled, “Suprachoroidal ...

Clearside Biomedical presented data on CLS-AX and its SCS delivery platform at the ARVO 2025 Meeting, highlighting treatment advancements for retinal diseases. Clearside Biomedical, Inc. has announced ...

Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector ®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a ...

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator ...

For author information and disclosures, see end of text. The most common complication of NIU and the primary condition associated with vision loss in uveitis is macular edema (ME), a central ...

- Presentations Highlight the Versatility of Clearside’s SCS Microinjector ® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be ...

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical firm pioneering therapies delivered through the suprachoroidal space (SCS®), announced today that Health Canada has officially approved ...

Patients with macular edema (ME) associated with uveitis (UME) are at risk for vision loss and decreased quality of life, and they often experience high health care costs and rates of workforce ...